Photolabile Compounds Visible Light Uncaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current photolabile compounds require ultraviolet (UV) light for uncaging, which can cause damage to tissues and cells, making them unsuitable for in vivo applications.
Innovation Solution
Development of novel photolabile compounds that can be uncaged using visible light, minimizing exposure to UV radiation and allowing precise control over the release of bioactive molecules in vivo.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If UV light is used to remove photolabile compounds, then the compounds can be effectively uncaged, but damage to organs, tissues and cells occurs
Solution Approach 1:
The patent changes the wavelength parameter of light from ultraviolet to visible light range. The photolabile compounds are designed to undergo cleavage upon exposure to visible light wavelengths (approximately 400-700 nm), which are less energetic and less harmful to biological tissues compared to UV light, thereby maintaining uncaging efficiency while reducing tissue damage
Solution Approach 2:
The patent converts the potentially harmful UV radiation requirement into a benefit by designing compounds that respond to visible light. This allows the use of safer, less energetic visible light to achieve the same photolabile compound removal effect, effectively turning the limitation of visible light lower energy into an advantage for in vivo applications
2Object-affected harmful factors
If visible light is used instead of UV light, then harm to biological samples is reduced, but the ability to uncage photolabile compounds is limited
Solution Approach 1:
The patent modifies the photophysical parameters of the uncaging system by incorporating metal-to-ligand charge transfer (MLCT) transitions in the photolabile compound design. These MLCT states enable efficient photochemistry upon visible light absorption, ensuring reliable uncaging capability while using safer visible light wavelengths
Solution Approach 2:
The patent employs composite photolabile compounds that combine organic ligand structures with metal centers (such as ruthenium or osmium complexes). This composite structure enables the material to absorb visible light through MLCT transitions and efficiently trigger the uncaging reaction, overcoming the limitation of using visible light instead of UV light
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the controlled release of bioactive molecules using visible light, reducing harm to biological samples and allowing localized and precise bioavailability of organic molecules, thereby overcoming the limitations of UV-dependent compounds.
Implementation Method 1
Upon exposure to light, the organic molecule is released
Data Source
AI summary
The present invention describes photolabile compounds and methods for use of the compounds. The photolabile compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect.